Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ProMIS Neurosciences Inc

PMN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$8.65

▼ -5.26%

Market Cap $80.53M · Vol 625

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$80.53M

Micro Cap

Div Yield

N/A

EPS Growth

+77.67%

YoY

RSI (14)

42.19

Momentum

Beta

-0.18

vs Market

52W High

$27.03

66.22% below

52W Low

$6.35

43.78% above

Volume

625

Avg 5.92K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

86.38%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ProMIS Neurosciences Inc (PMN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PMN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.57%

-35.88%

-38.17%

-22.14%

YTD

+26.09%

-18.16%

-80.45%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-39,719,150.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-282.76% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+77.67%
Outstanding Shares	8.97M

Technical Indicators

50-Day SMA	$12.00
200-Day SMA	$12.88
RSI (14)	42.19
Beta	-0.18
52-Week High	$27.03
52-Week Low	$6.35

Volume Today	625
Avg Daily Volume (30D)	5.92K
Relative Volume	0.11x
Volatility (10D)	96.52
Volatility (30D)	80.57
Free Float	86.38%

Analyst Consensus

BUY

Current Price $8.65

Mean Target $43.50

52W Low$6.35 52W High$27.03

Current

Target

$6.35 $27.03

Current Analyst target

+402.89% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SMDG62

ISINCA74346M5054

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.